Controlling opioid receptor functional selectivity by targeting distinct subpockets of the orthosteric site

  1. Rajendra Uprety
  2. Tao Che
  3. Saheem A Zaidi
  4. Steven G Grinnell
  5. Balázs R Varga
  6. Abdelfattah Faouzi
  7. Samuel T Slocum
  8. Abdullah Allaoa
  9. András Varadi
  10. Melissa Nelson
  11. Sarah M Bernhard
  12. Elizaveta Kulko
  13. Valerie LeRouzic
  14. Shainnel O Eans
  15. Chloe A Simons
  16. Amanda Hunkele
  17. Joan Subrath
  18. Ying Xian Pan
  19. Jonathan A Javitch
  20. Jay P McLaughlin
  21. Bryan L Roth  Is a corresponding author
  22. Gavril W Pasternak
  23. Vsevolod Katritch  Is a corresponding author
  24. Susruta Majumdar  Is a corresponding author
  1. Memorial Sloan Kettering Cancer Center, United States
  2. University of North Carolina, United States
  3. The Bridge Institute, University of Southern California, United States
  4. Columbia University, United States
  5. St. Louis College of Pharmacy and Washington University School of Medicine, United States
  6. Washington University in St. Louis, United States
  7. Washington University, United States
  8. University of Florida, United States
  9. University of Southern California, United States

Abstract

Controlling receptor functional selectivity profiles for opioid receptors is a promising approach for discovering safer analgesics; however, the structural determinants conferring functional selectivity are not well understood. Here we used crystal structures of opioid receptors, including the recently solved active state kappa opioid complex with MP1104, to rationally design novel mixed mu (MOR) and kappa (KOR) opioid receptor agonists with reduced arrestin signaling. Analysis of structure-activity relationships for new MP1104 analogs points to a region between transmembrane 5 (TM5) and extracellular loop (ECL2) as key for modulation of arrestin recruitment to both MOR and KOR. The lead compounds, MP1207 and MP1208, displayed MOR/KOR Gi-partial agonism with diminished arrestin signaling, showed efficient analgesia with attenuated liabilities, including respiratory depression and conditioned place preference and aversion in mice. The findings validate a novel structure-inspired paradigm for achieving beneficial in vivo profiles for analgesia through different mechanisms that include bias, partial agonism, and dual MOR/KOR agonism.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Rajendra Uprety

    Neurology, Memorial Sloan Kettering Cancer Center, New York, United States
    Competing interests
    Rajendra Uprety, RU have filed a provisional patent on MP1207 and related molecules..
  2. Tao Che

    Pharmacology, University of North Carolina, Chapel Hill, United States
    Competing interests
    No competing interests declared.
  3. Saheem A Zaidi

    Department of Biological Sciences, Molecular & Computational Biology, The Bridge Institute, University of Southern California, Los Angeles, United States
    Competing interests
    Saheem A Zaidi, SZ has filed a provisional patent on MP1207 and related molecules..
  4. Steven G Grinnell

    Molecular Therapeutics, Columbia University, New York, United States
    Competing interests
    No competing interests declared.
  5. Balázs R Varga

    Center for Clinical Pharmacology, St. Louis College of Pharmacy and Washington University School of Medicine, St Louis, United States
    Competing interests
    No competing interests declared.
  6. Abdelfattah Faouzi

    Clinical Pharmacology, Washington University in St. Louis, St Louis, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9059-4791
  7. Samuel T Slocum

    Pharmacology, University of North Carolina, Chapel Hill, United States
    Competing interests
    No competing interests declared.
  8. Abdullah Allaoa

    Neurology, Memorial Sloan Kettering Cancer Center, New York, United States
    Competing interests
    No competing interests declared.
  9. András Varadi

    Neurology, Memorial Sloan Kettering Cancer Center, New York, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5591-377X
  10. Melissa Nelson

    Molecular Therapeutics, Columbia University, New York, United States
    Competing interests
    No competing interests declared.
  11. Sarah M Bernhard

    Center for Clinical Pharmacology, Washington University, St Louis, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8549-0413
  12. Elizaveta Kulko

    Molecular Therapeutics, Columbia University, New York, United States
    Competing interests
    No competing interests declared.
  13. Valerie LeRouzic

    Neurology, Memorial Sloan Kettering Cancer Center, New York, United States
    Competing interests
    No competing interests declared.
  14. Shainnel O Eans

    Pharmacodyanamics, University of Florida, Gainesville, United States
    Competing interests
    No competing interests declared.
  15. Chloe A Simons

    Pharmacodyanamics, University of Florida, Gainesville, United States
    Competing interests
    No competing interests declared.
  16. Amanda Hunkele

    Neurology, Memorial Sloan Kettering Cancer Center, New York, United States
    Competing interests
    No competing interests declared.
  17. Joan Subrath

    Neurology, Memorial Sloan Kettering Cancer Center, New York, United States
    Competing interests
    No competing interests declared.
  18. Ying Xian Pan

    Neurology, Memorial Sloan Kettering Cancer Center, New York, United States
    Competing interests
    Ying Xian Pan, YXPis a co-founder of Sparian biosciences..
  19. Jonathan A Javitch

    Department of Psychiatry, Columbia University, New York, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7395-2967
  20. Jay P McLaughlin

    Pharmacodyanamics, University of Florida, Gainesville, United States
    Competing interests
    Jay P McLaughlin, JM has filed a provisional patent on MP1207 and related molecules..
  21. Bryan L Roth

    Department of Pharmacology, University of North Carolina, Chapel Hill, United States
    For correspondence
    bryan_roth@med.unc.edu
    Competing interests
    Bryan L Roth, BLR has filed a provisional patent on MP1207 and related molecules..
  22. Gavril W Pasternak

    Neurology, Memorial Sloan Kettering Cancer Center, New York, United States
    Competing interests
    Gavril W Pasternak, GWP is a co-founder of Sparian biosciences. GWP have filed a provisional patent on MP1207 and related molecules..
  23. Vsevolod Katritch

    Department of Biological Sciences, University of Southern California, Los Angeles, United States
    For correspondence
    katritch@usc.edu
    Competing interests
    Vsevolod Katritch, VK has filed a provisional patent on MP1207 and related molecules..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3883-4505
  24. Susruta Majumdar

    Center for Clinical Pharmacology, Washington University, st louis, United States
    For correspondence
    susrutam@email.wustl.edu
    Competing interests
    Susruta Majumdar, SM, is a co-founder of Sparian biosciences. SM have filed a provisional patent on MP1207 and related molecules..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2931-3823

Funding

National Institute on Drug Abuse (DA045884)

  • Susruta Majumdar

National Institute on Drug Abuse (DA045657)

  • Jonathan A Javitch

National Institute on Drug Abuse (DA046487)

  • Susruta Majumdar

National Institute on Alcohol Abuse and Alcoholism (AA026949)

  • Susruta Majumdar

National Institute on Drug Abuse (DA038858)

  • Vsevolod Katritch

National Institute on Drug Abuse (DA035764)

  • Bryan L Roth
  • Vsevolod Katritch

National Institute on Drug Abuse (DA007242,DA006241)

  • Ying Xian Pan
  • Gavril W Pasternak

National Institute on Drug Abuse (DA042888,DA046714)

  • Ying Xian Pan

National Institute of Mental Health (MH018870)

  • Steven G Grinnell

National Institute of Mental Health (MH112205)

  • Jonathan A Javitch

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All animal studies were preapproved by the Institutional Animal Care and Use Committees of University of Florida in accordance with the 2002 National Institutes of Health Guide for the Care and Use of Laboratory Animals. protocols 201808990 and 202011105.

Copyright

© 2021, Uprety et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,678
    views
  • 772
    downloads
  • 47
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Rajendra Uprety
  2. Tao Che
  3. Saheem A Zaidi
  4. Steven G Grinnell
  5. Balázs R Varga
  6. Abdelfattah Faouzi
  7. Samuel T Slocum
  8. Abdullah Allaoa
  9. András Varadi
  10. Melissa Nelson
  11. Sarah M Bernhard
  12. Elizaveta Kulko
  13. Valerie LeRouzic
  14. Shainnel O Eans
  15. Chloe A Simons
  16. Amanda Hunkele
  17. Joan Subrath
  18. Ying Xian Pan
  19. Jonathan A Javitch
  20. Jay P McLaughlin
  21. Bryan L Roth
  22. Gavril W Pasternak
  23. Vsevolod Katritch
  24. Susruta Majumdar
(2021)
Controlling opioid receptor functional selectivity by targeting distinct subpockets of the orthosteric site
eLife 10:e56519.
https://doi.org/10.7554/eLife.56519

Share this article

https://doi.org/10.7554/eLife.56519

Further reading

    1. Biochemistry and Chemical Biology
    Emily L Dearlove, Chatrin Chatrin ... Danny T Huang
    Research Article

    Ubiquitination typically involves covalent linking of ubiquitin (Ub) to a lysine residue on a protein substrate. Recently, new facets of this process have emerged, including Ub modification of non-proteinaceous substrates like ADP-ribose by the DELTEX E3 ligase family. Here, we show that the DELTEX family member DTX3L expands this non-proteinaceous substrate repertoire to include single-stranded DNA and RNA. Although the N-terminal region of DTX3L contains single-stranded nucleic acid binding domains and motifs, the minimal catalytically competent fragment comprises the C-terminal RING and DTC domains (RD). DTX3L-RD catalyses ubiquitination of the 3’-end of single-stranded DNA and RNA, as well as double-stranded DNA with a 3’ overhang of two or more nucleotides. This modification is reversibly cleaved by deubiquitinases. NMR and biochemical analyses reveal that the DTC domain binds single-stranded DNA and facilitates the catalysis of Ub transfer from RING-bound E2-conjugated Ub. Our study unveils the direct ubiquitination of nucleic acids by DTX3L, laying the groundwork for understanding its functional implications.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Marina Dajka, Tobias Rath ... Benesh Joseph
    Research Article

    Lipopolysaccharides (LPS) confer resistance against harsh conditions, including antibiotics, in Gram-negative bacteria. The lipopolysaccharide transport (Lpt) complex, consisting of seven proteins (A-G), exports LPS across the cellular envelope. LptB2FG forms an ATP-binding cassette transporter that transfers LPS to LptC. How LptB2FG couples ATP binding and hydrolysis with LPS transport to LptC remains unclear. We observed the conformational heterogeneity of LptB2FG and LptB2FGC in micelles and/or proteoliposomes using pulsed dipolar electron spin resonance spectroscopy. Additionally, we monitored LPS binding and release using laser-induced liquid bead ion desorption mass spectrometry. The β-jellyroll domain of LptF stably interacts with the LptG and LptC β-jellyrolls in both the apo and vanadate-trapped states. ATP binding at the cytoplasmic side is allosterically coupled to the selective opening of the periplasmic LptF β-jellyroll domain. In LptB2FG, ATP binding closes the nucleotide binding domains, causing a collapse of the first lateral gate as observed in structures. However, the second lateral gate, which forms the putative entry site for LPS, exhibits a heterogeneous conformation. LptC binding limits the flexibility of this gate to two conformations, likely representing the helix of LptC as either released from or inserted into the transmembrane domains. Our results reveal the regulation of the LPS entry gate through the dynamic behavior of the LptC transmembrane helix, while its β-jellyroll domain is anchored in the periplasm. This, combined with long-range ATP-dependent allosteric gating of the LptF β-jellyroll domain, may ensure efficient and unidirectional transport of LPS across the periplasm.